Xilio Therapeutics, Inc. (XLO) News
Follow Xilio Therapeutics, Inc. (XLO) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 5 public stories across 3 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Xilio Therapeutics, Inc. (XLO) Appoints Dr. Yariv J. Houvras as Chief Medical Officer
Xilio Therapeutics appointed Yariv J. Houvras, M.D., Ph.D. as chief medical officer, bringing 20+ years in clinical development and immuno-oncology.Material DetailsContext by AI AnalystThis is a management upgrade amid o
NEWS | Sep 28, 2026, 11:32 AM UTC
L
Xilio Therapeutics Appoints Yariv J. Houvras, M.D., Ph.D. as Chief Medical Officer
Dr. Houvras brings over two decades of executive leadership across premier industry and academic research institutions in clinical development, translational medicine and immuno-oncologyWALTHAM, Mass., Sept. 28, 2026 (GL
NEWS | Sep 28, 2026, 11:32 AM UTC
L
Xilio Therapeutics Appoints Yariv J. Houvras as Chief Medical Officer
Xilio Therapeutics Appoints Yariv J. Houvras as Chief Medical Officer
NEWS | Sep 28, 2026, 11:30 AM UTC
L
XLO: Xilio Therapeutics announces inducement grants under Nasdaq Rule 5635(c)(4)
Xilio Therapeutics said it will make inducement grants under Nasdaq Listing Rule 5635(c)(4).
EQUITY | Sep 02, 2026, 08:30 PM UTC
L
XLO Reports Q2 2026 Financial Results
Xilio Therapeutics reports second quarter 2026 financial results and provides pipeline updates
EARNINGS | Aug 12, 2026, 11:30 AM UTC